- Research Group Home Page:
In the Pharmacology & Drug Development Group we are taking novel drugs (small molecules and therapeutic antibodies) and drug combinations from in vitro assays through preclinical development and into Phase I clinical trials. Focused particularly on pancreatic cancer, using innovative cell-based and preclinical models, aiming to reduce the failure rate of cancer drug trials. I lead a team, supervise students, and manage scientific projects. I have 25 years’ research experience in academic oncology genetics, biology and pharmacology plus 6 years in commercial drug discovery and development. More than 70 publications, >6,000 citations; RG Score 40.73, h-index 37, i10 index 50.
- Work address:
- Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE
Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
E-pub date: 31 Dec 2018
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.
E-pub date: 11 Jun 2018
Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.
E-pub date: 01 Jun 2018
- Show allHide all